Prevnar 13 (Pfizer, 428f8e)

Prevnar 13 is a 13-valent pneumococcal conjugate vaccine developed by Wyeth (a subsidiary of Pfizer). It contains purified capsular polysaccharides from 13 different serotypes of *Streptococcus pneumoniae* (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F), each individually conjugated to a non-toxic diphtheria CRM197 carrier protein. This conjugation converts the T-cell independent polysaccharide antigens into T-cell dependent antigens, enhancing immunogenicity, particularly in infants and young children. The vaccine is indicated for the prevention of invasive pneumococcal disease, pneumonia, and otitis media caused by the included serotypes.

Brand names

Prevnar 13Prevnar13Prevnar-13Prevenar 13Prevenar13Prevenar-13

Other names

13-valent pneumococcal conjugate vaccinepneumococcal 13-valent conjugate vaccinepneumococcal13-valent conjugate vaccinepneumococcal-13-valent conjugate vaccinePneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein)